Dr Simon Agwale has a Ph.D. in virology and vaccinology. He has over 20 years’ experience combining top-level scientific research with the operations of Biotech companies.

Dr Simon Agwale was a Postdoc fellow at the Institute of Human Virology Baltimore, USA and Visiting Scientist at various institutions in Brazil, Germany, UK including the US Vaccine Research Centre/NIH, and US Centre for Disease Control and prevention in Atlanta. Dr Agwale was West Africa’s representative on HIV/AIDS for Developing countries Coordinating Committee (DCCC) at The European and Developing Countries Clinical Trials Programme (EDCTP), where he was also the chair of the African Scientists committee. He is a recipient of several scholarships, fellowships, and grants from reputable organizations around the world. He has also authored and co-authored numerous noteworthy publications.

Dr Agwale, Ph.D. is the CEO of Innovative Biotech, Nigeria, and Innovative Biotech USA Inc. He is a member of the board of the African Vaccine Manufacturing Initiative (AVMI) and Chair of Vaccine Technical working group. He is also an advisor to West Africa Health Organization (WAHO), and part of a recently established ECOWAS vaccines taskforce. He is currently the Lead of Bold Program 4 (Technology and IP) of the Partnerships for African Vaccine Manufacturing (PAVM) of Africa Centre for Disease Control and Prevention (Africa CDC).

Dr Agwale has a vision for the development and investigation of HIV vaccine constructs from prevalent Nigerian strains which are relevant to Nigerians. He is also currently developing novel vaccines against Covid-19, Ebola, HPV, and HIV using innovative viral-like particles (VLPs). Through INNOVATIVE, Dr Agwale is striving to further develop and refine these dynamic, novel treatments, and in doing so, expand domestic vaccine manufacturing capabilities in Nigeria to serve the African community.